Patent ID: 9695212
Date: 2017-07-04
CPC Classifications: A61K,A61P,C07H

Claim:
1. A method of inducing an immune response to a cancer in an individual, or inducing an immune response to a pathogen in an individual, comprising: parenterally administering to the individual in need thereof a composition comprising one or more cyclic purine dinucleotides or pharmaceutically acceptable salts thereof which induce STING-dependent TBK1 activation, wherein the cyclic purine dinucloetides present in the composition are thiophosphate cyclic purine dinucloetides that are substantially pure Rp,Rp diastereomers, or pharmaceutically acceptable salts thereof, wherein the 2′-OH substituent of either or both ribose moieties of the one or more cyclic purine dinucleotides is replaced with a substituent selected from the group consisting of fluorine, chlorine, bromine and iodine.